Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents

Plasma cell leukemia (PCL) is a rare hematologic malignancy with aggressive clinical and biologic features. Data regarding its prognosis with the use of the novel agents, i.e., the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, are limited. We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Talamo, Giampaolo, Dolloff, Nathan G., Sharma, Kamal, Zhu, Junjia, Malysz, Jozef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475946/
https://www.ncbi.nlm.nih.gov/pubmed/23087795
http://dx.doi.org/10.4081/rt.2012.e39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475946/
https://www.ncbi.nlm.nih.gov/pubmed/23087795
http://dx.doi.org/10.4081/rt.2012.e39

Ejemplares similares